Defeating Alzheimer's disease and other dementias: a priority for European science and society

Bengt Winblad; Philippe Amouyel; Sandrine Andrieu; Clive Ballard; Carol Brayne; Henry Brodaty; Angel Cedazo-Minguez; Bruno Dubois; David Edvardsson; Howard Feldman; Laura Fratiglioni; Giovanni B. Frisoni; Serge Gauthier; Jean Georges; Caroline Graff; Khalid Iqbal; Frank Jessen; Gunilla Johansson; Linus Jonsson; Miia Kivipelto; Martin Knapp; Francesca Mangialasche; Rene Melis; Agneta Nordberg; Marcel Olde Rikkert; Chengxuan Qiu; Thomas P. Sakmar; Philip Scheltens; Lon S. Schneider; Reisa Sperling; Lars O. Tjernberg; Gunhild Waldemar; Anders Wimo; Henrik Zetterberg

doi:https://doi.org/10.1016/S1474-4422(16)00062-4

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Bengt Winblad, Philippe Amouyel, Sandrine Andrieu, Clive Ballard, Carol Brayne, Henry Brodaty, Angel Cedazo-Minguez, Bruno Dubois, David Edvardsson, Howard Feldman, Laura Fratiglioni, Giovanni B. Frisoni, Serge Gauthier, Jean Georges, Caroline Graff, Khalid Iqbal, Frank Jessen, Gunilla Johansson, Linus Jonsson, Miia KivipeltoMartin Knapp, Francesca Mangialasche, Rene Melis, Agneta Nordberg, Marcel Olde Rikkert, Chengxuan Qiu, Thomas P. Sakmar, Philip Scheltens, Lon S. Schneider, Reisa Sperling, Lars O. Tjernberg, Gunhild Waldemar, Anders Wimo, Henrik Zetterberg

Research output: Contribution to journal › Article › Academic › peer-review

1065 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing populations worldwide. Even in high-income countries, the cost of medical care and associated societal burdens of dementia threaten to become overwhelming as more people live into old age. In view of the lack of progress in developing a cure for AD and the rapidly increasing costs of dementia, policy makers and governments have a powerful incentive to provide more resources to develop AD therapeutics. The Lancet Neurology Commission was formed with the overarching aim to provide information and expert recommendations to policy makers and political leaders about the growing problem of AD and related dementias of ageing.

Original language	English
Pages (from-to)	455-532
Journal	Lancet neurology
Volume	15
Issue number	5
DOIs	https://doi.org/10.1016/S1474-4422(16)00062-4
Publication status	Published - Apr 2016

Access to Document

https://doi.org/10.1016/S1474-4422(16)00062-4

Cite this

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G. B., Gauthier, S., Georges, J., Graff, C., Iqbal, K., Jessen, F., Johansson, G., Jonsson, L., ... Zetterberg, H. (2016). Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet neurology, 15(5), 455-532. https://doi.org/10.1016/S1474-4422(16)00062-4

@article{e573a40586d84f91991e7904e10a8f16,

title = "Defeating Alzheimer's disease and other dementias: a priority for European science and society",

abstract = "Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing populations worldwide. Even in high-income countries, the cost of medical care and associated societal burdens of dementia threaten to become overwhelming as more people live into old age. In view of the lack of progress in developing a cure for AD and the rapidly increasing costs of dementia, policy makers and governments have a powerful incentive to provide more resources to develop AD therapeutics. The Lancet Neurology Commission was formed with the overarching aim to provide information and expert recommendations to policy makers and political leaders about the growing problem of AD and related dementias of ageing.",

author = "Bengt Winblad and Philippe Amouyel and Sandrine Andrieu and Clive Ballard and Carol Brayne and Henry Brodaty and Angel Cedazo-Minguez and Bruno Dubois and David Edvardsson and Howard Feldman and Laura Fratiglioni and Frisoni, {Giovanni B.} and Serge Gauthier and Jean Georges and Caroline Graff and Khalid Iqbal and Frank Jessen and Gunilla Johansson and Linus Jonsson and Miia Kivipelto and Martin Knapp and Francesca Mangialasche and Rene Melis and Agneta Nordberg and Rikkert, {Marcel Olde} and Chengxuan Qiu and Sakmar, {Thomas P.} and Philip Scheltens and Schneider, {Lon S.} and Reisa Sperling and Tjernberg, {Lars O.} and Gunhild Waldemar and Anders Wimo and Henrik Zetterberg",

year = "2016",

month = apr,

doi = "https://doi.org/10.1016/S1474-4422(16)00062-4",

language = "English",

volume = "15",

pages = "455--532",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "5",

}

Winblad, B, Amouyel, P, Andrieu, S, Ballard, C, Brayne, C, Brodaty, H, Cedazo-Minguez, A, Dubois, B, Edvardsson, D, Feldman, H, Fratiglioni, L, Frisoni, GB, Gauthier, S, Georges, J, Graff, C, Iqbal, K, Jessen, F, Johansson, G, Jonsson, L, Kivipelto, M, Knapp, M, Mangialasche, F, Melis, R, Nordberg, A, Rikkert, MO, Qiu, C, Sakmar, TP, Scheltens, P, Schneider, LS, Sperling, R, Tjernberg, LO, Waldemar, G, Wimo, A & Zetterberg, H 2016, 'Defeating Alzheimer's disease and other dementias: a priority for European science and society', Lancet neurology, vol. 15, no. 5, pp. 455-532. https://doi.org/10.1016/S1474-4422(16)00062-4

TY - JOUR

T1 - Defeating Alzheimer's disease and other dementias: a priority for European science and society

AU - Winblad, Bengt

AU - Amouyel, Philippe

AU - Andrieu, Sandrine

AU - Ballard, Clive

AU - Brayne, Carol

AU - Brodaty, Henry

AU - Cedazo-Minguez, Angel

AU - Dubois, Bruno

AU - Edvardsson, David

AU - Feldman, Howard

AU - Fratiglioni, Laura

AU - Frisoni, Giovanni B.

AU - Gauthier, Serge

AU - Georges, Jean

AU - Graff, Caroline

AU - Iqbal, Khalid

AU - Jessen, Frank

AU - Johansson, Gunilla

AU - Jonsson, Linus

AU - Kivipelto, Miia

AU - Knapp, Martin

AU - Mangialasche, Francesca

AU - Melis, Rene

AU - Nordberg, Agneta

AU - Rikkert, Marcel Olde

AU - Qiu, Chengxuan

AU - Sakmar, Thomas P.

AU - Scheltens, Philip

AU - Schneider, Lon S.

AU - Sperling, Reisa

AU - Tjernberg, Lars O.

AU - Waldemar, Gunhild

AU - Wimo, Anders

AU - Zetterberg, Henrik

PY - 2016/4

Y1 - 2016/4

N2 - Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing populations worldwide. Even in high-income countries, the cost of medical care and associated societal burdens of dementia threaten to become overwhelming as more people live into old age. In view of the lack of progress in developing a cure for AD and the rapidly increasing costs of dementia, policy makers and governments have a powerful incentive to provide more resources to develop AD therapeutics. The Lancet Neurology Commission was formed with the overarching aim to provide information and expert recommendations to policy makers and political leaders about the growing problem of AD and related dementias of ageing.

AB - Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing populations worldwide. Even in high-income countries, the cost of medical care and associated societal burdens of dementia threaten to become overwhelming as more people live into old age. In view of the lack of progress in developing a cure for AD and the rapidly increasing costs of dementia, policy makers and governments have a powerful incentive to provide more resources to develop AD therapeutics. The Lancet Neurology Commission was formed with the overarching aim to provide information and expert recommendations to policy makers and political leaders about the growing problem of AD and related dementias of ageing.

U2 - https://doi.org/10.1016/S1474-4422(16)00062-4

DO - https://doi.org/10.1016/S1474-4422(16)00062-4

M3 - Article

SN - 1474-4422

VL - 15

SP - 455

EP - 532

JO - Lancet Neurology

JF - Lancet Neurology

IS - 5

ER -